GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (STU:0OT) » Definitions » 3-Year Revenue Growth Rate

Ocular Therapeutix (STU:0OT) 3-Year Revenue Growth Rate : 33.70% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Ocular Therapeutix 3-Year Revenue Growth Rate?

Ocular Therapeutix's Revenue per Share for the three months ended in Mar. 2024 was €0.10.

During the past 12 months, Ocular Therapeutix's average Revenue per Share Growth Rate was 0.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 33.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 73.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Ocular Therapeutix was 192.40% per year. The lowest was -11.50% per year. And the median was 47.95% per year.


Competitive Comparison of Ocular Therapeutix's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Ocular Therapeutix's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's 3-Year Revenue Growth Rate falls into.



Ocular Therapeutix 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Ocular Therapeutix  (STU:0OT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Ocular Therapeutix 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (STU:0OT) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (STU:0OT) Headlines

No Headlines